[
  {
    "criterion": "Provides a clear and concise explanation of the potential benefits and limitations of continuing immunotherapy after disease progression in advanced melanoma.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Incorrectly states that immunotherapy is never continued after disease progression in advanced melanoma.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Asks for clarification on the user's question or request for more information before providing an answer.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses technical jargon or overly complex language that may confuse an oncologist.",
    "axis": "communication_quality",
    "point": -6
  },
  {
    "criterion": "Fails to consider the potential risks and side effects associated with continuing immunotherapy after disease progression.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Provides evidence-based information on the effectiveness of continuing immunotherapy after disease progression in advanced melanoma.",
    "axis": "accuracy",
    "point": 6
  },
  {
    "criterion": "Advises seeking consultation with a medical oncologist or other relevant specialist before making a decision on continuing or switching therapy.",
    "axis": "instruction_following",
    "point": 8
  },
  {
    "criterion": "Mentions that the decision to continue or switch therapy should be based on the patient's individual circumstances and response to treatment.",
    "axis": "completeness",
    "point": 7
  },
  {
    "criterion": "Incorrectly states that immunotherapy is only effective for treating early-stage melanoma.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Provides a clear and concise explanation of the potential risks and benefits of continuing immunotherapy after disease progression in advanced melanoma.",
    "axis": "completeness",
    "point": 9
  }
]